Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.54 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705089 | 1.00 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL15165700 | 0.95 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL17525174 | 0.86 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705077 | 0.86 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20414881 | 0.86 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705075 | 0.86 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL8163475 | 0.86 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL16882307 | 0.83 | DPP7 (0.50) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL24677673 | 0.81 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL26431362 | 0.81 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3661922-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Dyax Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP7 496/4885GNAI3 1572/4885GNAO1 2091/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | DPP7 496/4885GNAI3 1572/4885GNAO1 2091/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP7 496/4885GNAI3 1572/4885GNAO1 2091/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP7 496/4885GNAI3 1572/4885GNAO1 2091/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | DPP7 496/4885GNAI3 1572/4885GNAO1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.